Cancers that
keep coming back…

Meet doctors
who never give up


Omico is providing free Comprehensive Genomic Profiling (CGP) to patients with advanced and incurable cancers to identify potential matches to clinical trials with new targeted therapies. 

Omico is also attracting more international precision oncology trials to Australia to increase treatment options for patients.

Cancer Meet Its Match

Opportunities for the clinical community


Why collaborate with Omico?


Get help finding and triaging trial options for your patients.


Access comprehensive genomic profiling at no cost to your patient to identify clinical trials and treatments specific to your patient’s cancer sub-type.


Get faster, curated and qualified recommendations.


Get support setting up clinical trials that may have previously been impossible due to low patient numbers.

How our genomic screening works

Appropriate patients with later-stage cancer that is not responding to current treatment or at high-risk for cancer (due to hereditary conditions):

  • You complete an online referral form
  • The patient signs a consent form
  • Cancer tissue undergoes molecular profiling
  • Molecular Tumour Board matches results to an existing therapy or clinical trial of a new drug
  • Process takes 8 to 10 weeks

How Omico streamlines research

Omico is proactively screening thousands of patients with comprehensive genomic profiling to streamline clinical trial enrolment and save costs.

Standard biomarker screening

Traditionally, biomarker screening is performed in each individual clinical trial. This inefficient method contributes significant costs to running a clinical trial, costing in the region of AUD $10M to identify 200 trial participants.

per test
per patient identified
specific biomarkers per $10M

Comprehensive genomic profiling

CGP is a next-generation screening approach that looks for hundreds of cancer biomarkers for multiple trials all at the same time. This more efficient method costs in the region of AUD $10 M to identify 400 trial participants for multiple clinical trials, a significant cost saving.

per test
per patient identified
specific biomarkers per $10M

Our Progress

10,500+ Patients screened
800 Referring clinicians
6,454     Patients with a treatment recommendation
786 Clinical trial referrals (C1/C2)

Referring patients to our programs

Cancer Screening Program

Our Cancer Screening Program (CaSP) brings comprehensive genomic profiling to patients with advanced and incurable cancer and helping identify potential treatments or clinical trials.

Match a patient’s molecular changes to targeted therapy

Our Molecular Screening and Therapeutics (MoST) study aims to characterise molecular changes in a patient’s cancer that may help to identify a targeted therapy or clinical trial.

Identify the genetic basis of a patient’s cancer risk

We’re examining the genetic basis of inherited cancer with our Genetic Cancer Risk in the Young (RisC) study.

RisC and SMOC diagram

Improve the surveillance of patients at risk of multi-organ cancer

Our Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+) study is investigating and evaluating the surveillance practices used for people at high-risk of multi-organ cancer.

RisC and SMOC diagram

Learn more about the clinical trials we support


  • What will CaSP do?

    If your patient is eligible for the screening program we will:

    • Consent your patient into CaSP
    • Arrange to access tumour tissue held by a pathology centre
    • Arrange for collection of a blood sample
    • Have the tissue analysed (molecular profiling) by a NATA or CLIA/CAP accredited laboratory
    • Following review by our molecular oncology board (MOB), provide you with a report containing the tumour’s molecular profile and therapeutic recommendations including clinical trials plus a copy of the NATA report.
  • Is my patient eligible for CaSP?

    If you answer “yes” to the following statements your patient may be eligible for enrolment.

    Your patient:

    • is aged 16 years or older, with pathologically confirmed advanced and/or metastatic cancer of any histologic type or an earlier diagnosis of a poor prognosis cancer
    • has tissue available for molecular screening
    • is self-caring in all activities of daily living, and out of bed more than half of each day (ECOG performance status 0, 1 or 2)
  • How do I refer patients?

    To get your patient onto CaSP you will need to:

    • Complete the referral form (see the link below)
    • Supply a histopathology report for your patient and any relevant clinical information
    • Receive and discuss the results of the molecular screening test and MOB report with your patient
    • If appropriate refer your patient to a clinical trial or follow up on treatment options highlighted in the MOB report
    • Continue to provide us with follow up information about your patient.

    CaSP program referral form

Our network

Omico facilitates a nationwide network of research and treatment centres that facilitate, support and promote genomic cancer medicine.

Rare Cancer Australia

Rare Cancer Australia (RCA) provides support and advocacy for patients wishing to participate in Omico programs. If you or your family need advice or help, a place to learn or simply someone to listen, RCA can help.

Visit the RCA website


If you are aged from 12 to 25 and your world has been turned upside down by cancer, Canteen provides support as well as someone to talk to.

Visit the Canteen website

Australian Rare Cancer Portal

The Australian Rare Cancer (ARC) Portal is an online referral service that aims to improve outcomes and access to research for Australians diagnosed with rare cancer.

Working together with your cancer specialist, the ARC Portal offers expert clinical advice, particularly for Australians who live far away from major metropolitan centres where cancer centres may not be available.

Visit the ARC Portal

CaSP optimal specimen requirements

Information and guidance to the optimal specimen requirements as part of our Cancer Screening Program (CaSP)

Download PDF resource

Work with us to help patients access genomic profiling and innovative new therapies

Get in touch